Carcinoma HER2 Protein Overexpression Immunohistochemistry | HercepTest Positive | Equivalent Positive
Item
histologically or cytologically confirmed carcinoma that overexpresses her2 by immunohistochemistry (2+ or 3+ positivity by herceptest or equivalent).
boolean
C0007097 (UMLS CUI [1,1])
C1515560 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C1512416 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0205163 (UMLS CUI [3,1])
C1514241 (UMLS CUI [3,2])
Progressive Disease During Therapeutic procedure | Progressive Disease Post Therapeutic procedure
Item
progressive disease during or after last treatment regimen.
boolean
C1335499 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C1335499 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
History Treatment Appropriate Histology
Item
appropriate treatment history for histological entity.
boolean
C0262926 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C1548787 (UMLS CUI [1,3])
C4048239 (UMLS CUI [1,4])
ECOG performance status
Item
ecog performance status <= 1.
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy >= 3 month.
boolean
C0023671 (UMLS CUI [1])
Measurable Disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
Laboratory parameters | Organ function Total
Item
acceptable laboratory parameters and adequate organ reserve.
boolean
C0022877 (UMLS CUI [1,1])
C0449381 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2,1])
C0439810 (UMLS CUI [2,2])
Left ventricular ejection fraction
Item
baseline lvef >50%
boolean
C0428772 (UMLS CUI [1])
Exposure to Anthracyclines Lifetime | Doxorubicin | Equivalent
Item
lifetime anthracycline exposure > 350 mg/m2 of doxorubicin or equivalent
boolean
C0332157 (UMLS CUI [1,1])
C0282564 (UMLS CUI [1,2])
C4071830 (UMLS CUI [1,3])
C0013089 (UMLS CUI [2])
C0205163 (UMLS CUI [3])
Major surgery
Item
major surgery within four weeks before enrollment.
boolean
C0679637 (UMLS CUI [1])
Hypersensitivity Murine protein | Hypersensitivity Recombinant Proteins | Hypersensitivity Polysorbate 80 | Hypersensitivity Drug Formulation Excipient
Item
known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.
boolean
C0020517 (UMLS CUI [1,1])
C1699668 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0034861 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0032601 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0524527 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Neoplasms, Second Primary | Absence Remission Duration | Exception Skin carcinoma Treated | Exception Carcinoma in situ of uterine cervix Biopsy | Exception Squamous intraepithelial lesion Pap smear | Exception Prostate carcinoma Localized Gleason score | Exception Melanoma in situ Resected
Item
second primary malignancy that has not been in remission for greater than 3 years. treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous intraepithelial lesion on pap smear, localized prostate cancer (gleason score < 6), or resected melanoma in situ are exceptions and do not require a 3 year remission.
boolean
C0085183 (UMLS CUI [1])
C0332197 (UMLS CUI [2,1])
C0687702 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C0005558 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0333873 (UMLS CUI [5,2])
C0079104 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
C0392752 (UMLS CUI [6,3])
C3203027 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C0854696 (UMLS CUI [7,2])
C1521996 (UMLS CUI [7,3])
Virus Disease | Bacterial Infection | Systemic mycosis | Requirement Parenteral therapy | Patient need for Antiviral Therapy Oral | Patient need for Antifungal therapy Oral | Patient need for Anti-Bacterial Agents Oral | Treatment completed Required
Item
active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
boolean
C0042769 (UMLS CUI [1])
C0004623 (UMLS CUI [2])
C0553576 (UMLS CUI [3])
C1514873 (UMLS CUI [4,1])
C0259961 (UMLS CUI [4,2])
C0686904 (UMLS CUI [5,1])
C0280274 (UMLS CUI [5,2])
C1527415 (UMLS CUI [5,3])
C0686904 (UMLS CUI [6,1])
C0678026 (UMLS CUI [6,2])
C1527415 (UMLS CUI [6,3])
C0686904 (UMLS CUI [7,1])
C0279516 (UMLS CUI [7,2])
C1527415 (UMLS CUI [7,3])
C0580352 (UMLS CUI [8,1])
C1514873 (UMLS CUI [8,2])
Chronic infectious disease | Recurrent infections | Requirement Antiviral Agents | Requirement Antifungal Agents | Requirement Anti-Bacterial Agents
Item
history of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.
boolean
C0151317 (UMLS CUI [1])
C0239998 (UMLS CUI [2])
C1514873 (UMLS CUI [3,1])
C0003451 (UMLS CUI [3,2])
C1514873 (UMLS CUI [4,1])
C0003308 (UMLS CUI [4,2])
C1514873 (UMLS CUI [5,1])
C0279516 (UMLS CUI [5,2])
Deep Vein Thrombosis | Pulmonary Embolism | Myocardial Infarction | Cerebrovascular accident
Item
history of deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke within three months of enrollment.
boolean
C0149871 (UMLS CUI [1])
C0034065 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0038454 (UMLS CUI [4])
CNS metastases | Residual disease | Recurrent disease
Item
known history of central nervous system (cns) metastatic disease with evidence of residual or recurrent disease upon entry.
boolean
C0686377 (UMLS CUI [1])
C0543478 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
Heart Disease New York Heart Association Classification
Item
new york heart association class iii or iv heart disease.
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])